Novartis has chosen Richard Saynor, currently senior vice-president of Classic & Established Products, Commercial & Digital Platforms at GlaxoSmithKline, to lead its Sandoz generics and biosimilars division. He will take over from interim head Francesco Balestrieri “no later than 1 August 2019” and will report directly to Novartis CEO Vas Narasimhan as a member of the Swiss group’s executive committee.
Saynor previously spent around five years with Sandoz, initially leading its operations in around 65 markets as head of Asia,...




